Our Mission

Pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease

Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. We are defined by our core competencies including deep therapeutic knowledge and operational effectiveness. Viela Bio, driven by our talented research and development team, is currently focused on:

  • Delivering the inebilizumab phase 2 clinical study
  • Efficiently developing the early stage portfolio
  • Exploring existing and novel pathways to develop next generation inflammation and autoimmune therapies

Our Investors

Together with Temasek, Terra Magnum Capital Partners and Barer & Son Capital